Athenex to Provide Corporate and Financial Update for the Fourth Quarter and Full Year 2021, on March 15, 2022

Rhea-AI Summary

Athenex (NASDAQ: ATNX), a leading global biopharmaceutical company focusing on cancer therapies, will provide a corporate and financial update for Q4 and full year 2021 on March 15, 2022. The management team will host a conference call and audio webcast at 8:00 a.m. Eastern Time.

To join the call, use the domestic number (877) 407-0784 or international number (201) 689-8560 with passcode 13726462. The live call and replay will also be accessible via the company’s Investor Relations website.

Positive

• Athenex's commitment to innovative cancer treatments through its three platforms: Oncology Innovation, Commercial, and Global Supply Chain.
• The anticipated corporate and financial update could provide insights into Athenex's strategic direction and performance.

Negative

• None.

BUFFALO, N.Y., March 07, 2022 (GLOBE NEWSWIRE) -- Athenex (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the Company will provide a corporate and financial update for the fourth quarter and full year 2021, on Tuesday, March 15, 2022. Athenex’s management team will host a conference call and live audio webcast at 8:00 a.m. Eastern Time.

To participate in the call, dial either the domestic or international number fifteen minutes before the conference call begins:

Domestic: (877) 407-0784

International: (201) 689-8560

Passcode: 13726462

The live conference call and replay can also be accessed via audio webcast here and on the Investor Relations section of the Company’s website under “Events and Presentations”, located at http://ir.athenex.com/.

About Athenex, Inc.

Founded in 2003, Athenex, Inc. is a global clinical-stage biopharmaceutical company dedicated to becoming a leader in the discovery, development, and commercialization of next generation drugs for the treatment of cancer. Athenex is organized around three platforms, including an Oncology Innovation Platform, a Commercial Platform, and a Global Supply Chain Platform. The Company’s current clinical pipeline is derived mainly from the following core technologies: (1) Orascovery, based on P-glycoprotein inhibitor, (2) Src kinase inhibition, and (3) Cell therapy. Athenex’s employees worldwide are dedicated to improving the lives of cancer patients by creating more active and tolerable treatments. For more information, please visit www.athenex.com.

Athenex Contacts

Investors

Daniel Lang, MD
Athenex, Inc.
Email: danlang@athenex.com

Caileigh Dougherty
Athenex, Inc.
Email: cdougherty@athenex.com

FAQ

When will Athenex announce its Q4 2021 financial update?

Athenex will announce its Q4 2021 financial update on March 15, 2022.

What time is Athenex's conference call for the financial update?

The conference call will be held at 8:00 a.m. Eastern Time on March 15, 2022.

How can I participate in Athenex's conference call?

To participate, dial (877) 407-0784 for domestic calls or (201) 689-8560 for international calls, using passcode 13726462.

Where can I access Athenex's conference call replay?

The replay of Athenex's conference call can be accessed via the Investor Relations section of the company’s website.

What platforms does Athenex focus on for cancer treatment?

Athenex focuses on three platforms: Oncology Innovation, Commercial, and Global Supply Chain.